Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Carboplatin/paclitaxel

Carboplatin/paclitaxel Reactions 1704, p87 - 2 Jun 2018 Worsening of pleural effusion and increasing respiratory distress: case report A 44-year-old man developed worsening of pleural effusion and increasing respiratory distress during treatment with carboplatin and paclitaxel [dosages and routes not stated]. The man was diagnosed with salivary gland secretory carcinoma and underwent a local excision. He was also found to have ETV6-NTRK3 fusion, CDKN2A/B loss and APC mutation. Two months post-operation, he presented with shortness of breath and increasing cough. He was found to have mediastinal lymphadenopathy, multiple pleural-based nodules and a large pleural effusion, which indicated metastatic disease. Adenocarcinoma was confirmed. He received one cycle of combined chemotherapy with paclitaxel and carboplatin. However, he developed complications of worsening pleural effusions and increasing respiratory distress [times to reactions onsets not stated]. One month after the start of therapy, there was progression in the size and number of pleural metastases. Therefore, the man was initiated on crizotinib during hospitalisation, which resulted in improvement in his respiratory symptoms and tolerance of exertion over the following weeks. After 10 weeks of crizotinib therapy, he returned to the hospital for worsening respiratory distress and was noted to have a progression of disease in the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Carboplatin/paclitaxel

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Carboplatin/paclitaxel

Abstract

Reactions 1704, p87 - 2 Jun 2018 Worsening of pleural effusion and increasing respiratory distress: case report A 44-year-old man developed worsening of pleural effusion and increasing respiratory distress during treatment with carboplatin and paclitaxel [dosages and routes not stated]. The man was diagnosed with salivary gland secretory carcinoma and underwent a local excision. He was also found to have ETV6-NTRK3 fusion, CDKN2A/B loss and APC mutation. Two months post-operation, he...
Loading next page...
 
/lp/springer_journal/carboplatin-paclitaxel-hfgnrzI8Vg
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46730-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p87 - 2 Jun 2018 Worsening of pleural effusion and increasing respiratory distress: case report A 44-year-old man developed worsening of pleural effusion and increasing respiratory distress during treatment with carboplatin and paclitaxel [dosages and routes not stated]. The man was diagnosed with salivary gland secretory carcinoma and underwent a local excision. He was also found to have ETV6-NTRK3 fusion, CDKN2A/B loss and APC mutation. Two months post-operation, he presented with shortness of breath and increasing cough. He was found to have mediastinal lymphadenopathy, multiple pleural-based nodules and a large pleural effusion, which indicated metastatic disease. Adenocarcinoma was confirmed. He received one cycle of combined chemotherapy with paclitaxel and carboplatin. However, he developed complications of worsening pleural effusions and increasing respiratory distress [times to reactions onsets not stated]. One month after the start of therapy, there was progression in the size and number of pleural metastases. Therefore, the man was initiated on crizotinib during hospitalisation, which resulted in improvement in his respiratory symptoms and tolerance of exertion over the following weeks. After 10 weeks of crizotinib therapy, he returned to the hospital for worsening respiratory distress and was noted to have a progression of disease in the

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

References

  • Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib.
    Cipriani, NA